SNY - Sanofi

NYSE - NYSE Delayed Price. Currency in USD
40.36
+0.25 (+0.62%)
At close: 4:02PM EDT

40.32 -0.04 (-0.09%)
After hours: 4:03PM EDT

Stock chart is not supported by your current browser
Previous Close40.11
Open40.38
Bid40.37 x 800
Ask40.60 x 200
Day's Range40.07 - 40.51
52 Week Range39.93 - 40.51
Volume922,461
Avg. Volume1,178,800
Market Cap101.529B
Beta0.83
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.86 (4.64%)
Ex-Dividend Date2018-05-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • What Wall Street Analysts Estimate for Johnson & Johnson
    Market Realist11 hours ago

    What Wall Street Analysts Estimate for Johnson & Johnson

    Johnson & Johnson (JNJ) surpassed EPS (earnings per share) and revenue estimates in 1Q18. For 1Q18, Johnson & Johnson reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against the estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q18.

  • Analysts’ Views on Sanofi, Pre-1Q18 Earnings Release
    Market Realistyesterday

    Analysts’ Views on Sanofi, Pre-1Q18 Earnings Release

    In 1Q18, analysts expect Sanofi’s (SNY) revenue to fall ~6.6% YoY (year-over-year) to 8.1 billion euros from 8.7 billion euros, and its earnings per share to fall to 1.13 euros from 1.42 euros. Sanofi’s stock price has fallen ~9.4% over the last 12 months and ~7.1% year-to-date. Analysts’ price target of $47.67 suggests the stock could return ~19.2% over the next 12 months based on its price of $39.95 on April 23.

  • Sanofi’s 1Q18: Revenue Expected to Fall
    Market Realistyesterday

    Sanofi’s 1Q18: Revenue Expected to Fall

    As discussed earlier, analysts expect Sanofi’s (SNY) revenue to fall 6.6% to 8.1 billion euros in 1Q18. Let’s look at Sanofi’s segment-wise expectations.

  • Analysts’ Estimates for Sanofi’s 1Q18 Earnings
    Market Realistyesterday

    Analysts’ Estimates for Sanofi’s 1Q18 Earnings

    Paris-headquartered Sanofi (SNY), one of the world’s largest pharmaceutical companies, reports its financial results in euros. The company is set to release its 1Q18 earnings on April 27. Analysts expect Sanofi to report EPS (earnings per share) of 1.13 euros and revenue of 8.1 billion euros.

  • A Review of Novo Nordisk’s Modern Insulin
    Market Realistyesterday

    A Review of Novo Nordisk’s Modern Insulin

    Novo Nordisk’s (NVO) modern insulins include NovoRapid, Levemir, and NovoMix. In 4Q17, its modern insulins generated revenues of 10.4 billion Danish kroner, which is a ~9% YoY (year-over-year) decline in local currency.

  • Novo Nordisk’s New-Generation Insulins: Growth Driver for 2018?
    Market Realistyesterday

    Novo Nordisk’s New-Generation Insulins: Growth Driver for 2018?

    Novo Nordisk’s (NVO) new-generation insulin portfolio consists of Tresiba, Xultophy, Ryzodeg, and Fiasp.

  • Novo Nordisk’s Xultophy Expected to See High Growth in 2018
    Market Realistyesterday

    Novo Nordisk’s Xultophy Expected to See High Growth in 2018

    In fiscal 2017, Novo Nordisk’s (NVO) Xultophy generated revenues of 729 million Danish kroner compared to 207 million Danish kroner in 2016. That’s a ~255% YoY (year-over-year) growth in local currency.

  • Reuters2 days ago

    Boehringer's operating income up 20.7 percent on Sanofi deal

    Boehringer Ingelheim, Germany's second-largest drugmaker, posted a gain in operating income of 20.7 percent to 3.5 billion euros (3.06 billion pounds) last year, boosted by the purchase of Sanofi's (SASY.PA) veterinary medicine. The asset swap saw unlisted Boehringer take Sanofi's $13.5 billion animal health subsidiary, making it the world's second-largest player in the industry after Zoetis (ZTS.N). In return, Sanofi obtained the German company's consumer health care business unit, valued at nearly $8 billion, plus $5.5 billion in cash from Boehringer, which Boehringer at the time paid largely from existing liquidity on its balance sheet.

  • Reuters2 days ago

    Boehringer's operating income up 20.7 percent on Sanofi deal

    Boehringer Ingelheim, Germany's second-largest drugmaker, posted a gain in operating income of 20.7 percent to 3.5 billion euros ($4.27 billion) last year, boosted by the purchase of Sanofi's veterinary medicine. The asset swap saw unlisted Boehringer take Sanofi's $13.5 billion animal health subsidiary, making it the world's second-largest player in the industry after Zoetis. In return, Sanofi obtained the German company's consumer health care business unit, valued at nearly $8 billion, plus $5.5 billion in cash from Boehringer, which Boehringer at the time paid largely from existing liquidity on its balance sheet.

  • Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018
    Market Realist2 days ago

    Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018

    In 4Q17, Novo Nordisk’s (NVO) Tresiba generated revenues of 1.9 billion Danish kroner, which is a ~48% YoY (year-over-year) growth in local currency.

  • With deadline looming, Takeda nears agreement to buy Shire, says Bloomberg
    American City Business Journals2 days ago

    With deadline looming, Takeda nears agreement to buy Shire, says Bloomberg

    The merger would create a company that would rival Sanofi Genzyme as the largest life sciences employer in Massachusetts.

  • Reuters3 days ago

    UK bans Sanofi epilepsy drug without pregnancy prevention plan

    A Sanofi (SASY.PA) drug for epilepsy and bipolar disorder linked to thousands of birth defects has been banned in Britain for use in women or girls of child-bearing age, unless they are on a special pregnancy prevention programme. The move follows a scandal over the lack of information given to patients about the risks associated with valproate, which was first approved in France in 1967 and remains a widely used treatment for epilepsy. It is sold by Sanofi under the brand Depakine for epilepsy and Depakote and Depamide for bipolar disorders.

  • Sanofi (EPA:SAN): Immense Growth Potential?
    Simply Wall St.3 days ago

    Sanofi (EPA:SAN): Immense Growth Potential?

    Sanofi’s (ENXTPA:SAN) latest earnings announcement in December 2017 showed that the business experienced a significant headwind with earnings declining by -13.74%. Today I want to provide a brief commentary onRead More...

  • Motley Fool6 days ago

    Why Dicerna Rocketed Higher Today

    Investors are happy the biotech ended a lawsuit hanging over its head.

  • Reuters7 days ago

    WHO recommends testing before use of Sanofi's dengue vaccine

    The World Health Organisation on Thursday said Sanofi's vaccine against dengue should only be used after testing individuals to assess whether they could have been exposed before to the infection. "We have now clear information that the vaccine needs to be dealt in a safer way by using it exclusively in people already infected," Alejandro Cravioto, Chair of the WHO's Strategic Advisory Group of Experts (SAGE) on Immunization, told journalists. After new analysis of data, Sanofi warned in November the vaccine could increase the risk of severe dengue in some cases in people who had not been previously exposed to the disease.

  • Sanofi to Divest European Generic Unit, Streamline Business
    Zacks7 days ago

    Sanofi to Divest European Generic Unit, Streamline Business

    Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.

  • Analysts’ Recommendations for Novartis on April 17
    Market Realist8 days ago

    Analysts’ Recommendations for Novartis on April 17

    Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16. For 1Q18, analysts expect Novartis to see EPS of $1.28 on revenue of $12.6 billion.

  • Novartis’s 1Q18 Estimates: Expectations for Sandoz
    Market Realist8 days ago

    Novartis’s 1Q18 Estimates: Expectations for Sandoz

    Sandoz, the generics arm of Novartis (NVS), includes pharmaceuticals and biotechnological active substances in its portfolio. Sandoz is expected to report growth in operating revenue in 1Q18.

  • Reuters9 days ago

    Sanofi's CFO Contamine to retire later this year

    PARIS (Reuters) - Sanofi's (SASY.PA) executive vice president and chief financial officer, Jerome Contamine, plans to retire later this year, the French drugmaker said on Tuesday. In an emailed statement, ...

  • Sanofi Finance Chief to Leave After Almost a Decade at Drugmaker
    Bloomberg9 days ago

    Sanofi Finance Chief to Leave After Almost a Decade at Drugmaker

    Sanofi Chief Financial Officer Jerome Contamine is planning to step down from the French drugmaker later this year after almost a decade in the job.

  • Novartis’s Innovative Medicines Segment in 1Q18
    Market Realist9 days ago

    Novartis’s Innovative Medicines Segment in 1Q18

    Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products.

  • The Wall Street Journal9 days ago

    [$$] Advent in Exclusivity to Buy Czech Drugmaker Zentiva for €1.9 Billion

    The firm has presented a €1.9 billion ($2.35 billion) binding offer for the drugmaker.

  • In Pharma, If You Can't Join Them, Beat Them
    Bloomberg9 days ago

    In Pharma, If You Can't Join Them, Beat Them

    Advent is preparing to take on a drugmaker it tried and failed to buy.

  • Reuters9 days ago

    Bank trio expected to lead financing on Zentiva sale

    Goldman Sachs, JP Morgan and Morgan Stanley are expected to lead a debt financing totalling in excess of €1bn backing private equity firm Advent International’s acquisition of French healthcare group Sanofi’s (SASY.PA) European generics drugs arm Zentiva, banking sources said. Sanofi entered exclusive talks to sell Zentiva to Advent for €1.9bn, including equity and debt, the companies said on Tuesday.

  • Sanofi in talks to sell generics arm for $2.4 bln
    Reuters Videos9 days ago

    Sanofi in talks to sell generics arm for $2.4 bln

    French healthcare group Sanofi is in exclusive talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for 1.9 billion euros ($2.4 billion). Sonia Legg reports.